PAREXEL INTERNATIONAL NAMES SUSAN MURPHY WARREN VICE PRESIDENT, CORPORATE MARKETING AND STRATEGY
BOSTON, MA, October 1, 2001 — PAREXEL International Corporation (Nasdaq: PRXL) today announced the appointment of Susan Murphy Warren as Vice President, Corporate Marketing and Strategy. In this capacity, Ms. Murphy Warren will oversee the management and administration of the Company’s marketing, public relations and strategic planning activities worldwide.
Ms. Murphy Warren possesses over 18 years of extensive management experience in the biomedical industry in marketing, strategic planning and commercial operations. Prior to joining PAREXEL, she held a variety of high level positions with Ciba-Corning (Novartis), Chiron, and Bayer, including Director, Worldwide Marketing, Disease Focus at Bayer Diagnostics. Most recently, she was Vice President, Marketing & Sales at Mosaic Technologies, Inc., a genomics tools company serving the pharmaceutical and biotechnology industries. She received her M.B.A. from Harvard University and M.A. in International Studies from the American University.
“We are extremely pleased to add Susan to our organization. Her broad experience in marketing, strategic planning and sales management make her extremely well-suited to assume her new responsibilities as Vice President, Corporate Marketing and Strategy,” said Josef H. von Rickenbach, Chairman and Chief Executive Officer. “Susan has a keen understanding of what is needed to compete effectively in today’s competitive environment and strengthen PAREXEL’ s position in the marketplace.”
PAREXEL is one of the largest contract pharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., provides a variety of technology products and services, including web-based portal solutions and voice and data systems, which are designed to accelerate and enhance the clinical development and launch processes. The Company’s integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 54 locations throughout 35 countries around the world, and has approximately 4,695 Employees.
This release may contain "forward-looking" statements regarding future results and events, including statements regarding expected financial results, future growth and customer demand that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears" and similar expressions are intended to identify forward-looking statements. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the cancellation, revision, or delay of contracts, including those contracts in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of certain industries and clients; competition and consolidation within the pharmaceutical industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Form 10-K for the period ended June 30, 2001, as filed with the Securities and Exchange Commission.